The qualifications include being an adult with a body mass index (BMI) of at least 30 mg/kg or higher, or a BMI of 27 mg/kg or higher, along with a minimum of one weight-related condition such as type 2 diabetes, high blood pressure, or high cholesterol
Food and Drug Administration (FDA) approved the use of semaglutide injections for chronic weight management in adults with obesity or overweight conditions, particularly those with at least one weight-related condition such as high blood pressure, type 2 diabetes, or high cholesterol
This shift could make it much more challenging for people relying on compounded medications to continue their weight loss journey
For patients serious about understanding their unique metabolic response, the Precision Peptide Genetic Test ($99 add-on) unlocks actionable data about your GLP-1 pathway efficiency, helping your provider fine-tune your semaglutide dose or consider alternatives like oral semaglutide ($289/mo), tirzepatide ($289/mo injection, $279/mo oral), or GLP-Squared dual compounds ($289/mo injection, $389/mo oral) based on your genetic blueprint rather than guesswork
Reddy's version became available in Canada on May 15, according to the BMJ [Source: bmj.com/content/393/bmj-2026-597166]
Semaglutide GLP-1 injections come as a fresh approach to medical weight loss in that it has been shown to provide much more significant results than other options that are available on the market when used alongside a healthy diet and exercise regimen
